WeightControl.com Interview with:
Deborah B. Horn, DO, MPH, FOMA
Medical Director for Center of Obesity Medicine and Metabolic Performance
McGovern Medical School
UTHealth Houston, Texas
A new sub-group analysis of two major clinical trials examines how the oral GLP-1 medication orforglipron performs in adults aged 65 and older — with encouraging findings on both efficacy and safety.WeightControl.com: What is the background for this study? What are the main findings?
Response: The ATTAIN-1 and ATTAIN-2 trials studied orforglipron in individuals with obesity with and without diabetes. This sub-hoc analysis looked at the subgroup of individuals in both of these trials that were aged 65 and older and found significantly greater reductions in body weight and HbA1c, a marker of diabetes, compared to placebo. And encouragingly, the safety and side effect profiles were consistent with the overall populations and with other GLP-1 medications.
WeightControl.com: How does orforglipron differ from other GLP-1 medications for obesity?
Response: While many individuals manage injectable GLP-1 medication without difficulty, a daily oral may be more attractive to patients for many reasons, regardless of age.
WeightControl.com: What should readers take away from your report?
Response: The clinical implications allow primary care providers and specialists to feel confident that the results in our older patients are similar to our broader practice population in weight loss, diabetes improvement, and safety. We can feel confident prescribing orforglipron to our patients 65 and older.
WeightControl.com: What recommendations do you have for future research as a result of this work?
- Studies are already underway to look more carefully not just at muscle mass, but also muscle quality, muscle function, mobility, and quality of life to better understand muscle changes with GLP-1.
- We need continued research in special populations, including older patients, peri/post menopausal women, and many more.
Disclosures: Dr. Horn does consulting for Lilly, the maker of orforglipron, and receives institutional research funds as a principal investigator.
Citation:
Late-breaking poster abstract 1705 at the European Congress on Obesity (ECO) in Istanbul, Turkey, 12–15 May 2026
Orforglipron for Obesity Treatment in Older Patients ≥65 Years With or Without Type 2 Diabetes
Authors: Deborah B. Horn, Alpana P. Shukla, Haocheng Huang, Elvis Twum, Sanja Giljanovic Kis
Disclaimer: The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on May 11, 2026 by weightcontrol